Elaine V. Jones - Vice President, Venture Capital, Pfizer Inc
Short description of the presentation:
In 2016, Pfizer announced an expansion of its investment strategy to target early-stage companies on the leading edge of scientific innovation, providing both equity and access to resources for research in promising areas aligned with Pfizer’s core interests. Through such flexible equity investment and partnership models, Pfizer will provide access to world-class scientists, expertise and drug-discovery capabilities, including enabling proprietary technologies, and actively participate in the development of early-stage innovations. The ultimate goal of these investments is to accelerate the pace at which good scientific ideas can become promising therapies. Investments are focused in high-priority therapeutic areas of research at Pfizer, which include chronic inflammatory and autoimmune diseases, vaccines, oncology, neuroscience and pain, cardiovascular and metabolic disease, and rare diseases. Dr. Jones will provide an update on the current portfolio and future direction of this investment initiative.
Biography of the speaker:
Elaine V. Jones, Ph.D. joined Pfizer Venture Investments as Executive Director, Venture Capital in 2008. She is responsible for making and managing venture investments for Pfizer and currently oversees the PVI investments in Autifony Therapeutics Ltd. (London, UK), Blade Therapeutics (South San Francisco, CA), Mersana Therapeutics (Cambridge, MA), MISSION Therapeutics (Cambridge, UK), Nimbus Therapeutics LLC. (Cambridge, MA), Quartet Medicine (Cambridge, MA), Second Genome (San Francisco, CA), Storm Therapeutics (Cambridge, UK), and Ziarco Pharma (Canterbury, UK). Elaine brings 17 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team.
Most recently, Elaine was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.
Prior to joining ESR, Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron. Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D.
Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.